Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company

Cytiva Announces RMB 60M Investment for China Science Innovation Center at CIIE

Fineline Cube Nov 7, 2022

Cytiva—formerly GE Healthcare Life Sciences and now the life science platform of Danaher Corporation—announced at...

Company Drug

Innovent Biologics’ Tafolecimab Shows Strong LDL-C Reduction in Phase III Study

Fineline Cube Nov 7, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) announced the results of the Phase III CREDIT-1 study...

Company Drug

Ascentage Pharma Presents APG-1387 Phase I Study Results at AASLD

Fineline Cube Nov 7, 2022

Hong Kong-based biotech Ascentage Pharma (HKG: 6855) presented the Phase I clinical study results of...

Company Deals

Allergan Aesthetics Partners with Sinopharm at CIIE for Aesthetic Medicine

Fineline Cube Nov 7, 2022

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced a partnership with Sinopharm Group Co.,...

Company Deals

Honeywell Partners with Anruite for Smart Manufacturing in China

Fineline Cube Nov 7, 2022

US major Honeywell (NASDAQ: HON) has announced a partnership with China-based Tonghua Anruite Biopharmaceutical Co.,...

Company Deals

Boehringer Ingelheim Launches Rehabilitation Center in Chengdu at CIIE

Fineline Cube Nov 7, 2022

The 5th China International Import Expo (CIIE) saw the unveiling of Boehringer Ingelheim’s Consanas (Chengdu)...

Company Deals

Fosun Pharma Partners with Soong Ching Ling Foundation for Women and Children’s Health

Fineline Cube Nov 7, 2022

The 5th China International Import Expo (CIIE) saw Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:...

Company Deals

Jumpcan Partners with Newsoara for PDE4 and Protease Inhibitors in China

Fineline Cube Nov 7, 2022

China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a partnership with compatriot firm Newsoara BioPharma Co.,...

Company

Novo Nordisk to Invest RMB 400M in Shanghai at CIIE

Fineline Cube Nov 7, 2022

Novo Nordisk (NYSE: NVO) has announced at the 5th China International Import Expo (CIIE) an...

Company Drug

Jiangsu Yahong Initiates Phase III Study for Hexvix in Bladder Cancer Detection

Fineline Cube Nov 7, 2022

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced the...

Company Drug

Betta Pharmaceuticals’ BPI-452080 Accepted for Review by NMPA

Fineline Cube Nov 7, 2022

China’s Betta Pharmaceuticals (SHE: 300558) has announced that a clinical trial filing for its Category...

Company Drug

Qilu Regor’s RGT-264 Phosphate Tablets Approved for Phase I Study

Fineline Cube Nov 4, 2022

China-based biotech Qilu Regor Therapeutics Inc has announced receiving approval from the National Medical Products...

Company Deals

Hainan Free Trade Port to Simplify Drug Import Procedures

Fineline Cube Nov 4, 2022

The “Provisions on Facilitation of Drug Import in Hainan Free Trade Port,” released in September...

Policy / Regulatory

Hainan Free Trade Port to Simplify Drug Import Procedures

Fineline Cube Nov 4, 2022

The “Provisions on Facilitation of Drug Import in Hainan Free Trade Port,” released in September...

Company Drug

Sinovac’s Varicella Vaccine Receives WHO Pre-Qualification

Fineline Cube Nov 4, 2022

China-based Sinovac has announced receiving pre-qualification (PQ) status from the World Health Organization (WHO) for...

Company Drug

Reforgene Medicine RM-001 Thalassemia Gene Editing

Fineline Cube Nov 4, 2022

China-based Guangzhou Reforgene Medicine Co., Ltd’s in-house developed β-thalassemia gene editing drug RM-001 (HBG gene...

Company Drug

Walvax Biotech Launches Phase IIIb Trial for mRNA COVID-19 Vaccine

Fineline Cube Nov 4, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the initiation of a Phase IIIb...

Company Drug

Guangdong Zhongsheng Initiates Phase III Study for RAY1216 in COVID-19

Fineline Cube Nov 4, 2022

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the initiation of a randomized,...

Company

Bloomage Biotech CEO Investigated Over Discounted Share Sales

Fineline Cube Nov 4, 2022

The chairwoman of Chinese medical aesthetics player Bloomage Biotech Corp., Ltd (SHA: 688363), Ms. Zhao...

Policy / Regulatory

NMPA Proposes ‘Drug Online Sales Blacklist’ for Public Feedback

Fineline Cube Nov 4, 2022

The National Medical Products Administration (NMPA) has released a draft proposal for a “Drug Online...

Posts pagination

1 … 659 660 661 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.